Marker Therapeutics, Inc. — Director's Dealing 2016

Jan 28, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TAPIMMUNE INC (TPIV)
CIK: 0001094038
Period of Report: 2016-01-26

Reporting Person: Wasserman Frederick Gerald (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-01-26	Employee Stock Option (Right to Buy)	$0.63	A	150000	Acquired	2026-01-26	Common Stock (150000)	Direct

Footnotes

F1: Represents options granted in connection with appointment as a director of the Company on January 26, 2016 under the Company's 2014 Omnibus Stock Ownership Plan. These shares shall vest monthly over a two year period. The option exercise price is the closing price on the date of the grant, January 26, 2016.